Genome Canada, the Ontario Institute for Cancer Research (OICR) and Thermo Fisher Scientific are collaborating to d...
Alizé Pharma 3, a company specialized in developing therapeutic peptides for rare endocrine and metabolic di...
Pfizer Inc. announced the successful completion of its acquisition of Array BioPharma Inc., advancing breakthrough...
US based Exact Sciences Corp. and Genomic Health, Inc. have announced that the companies have entered into a d...
Dassault Systèmes has announced the five-year extension of its collaboration with the U.S. Food and Drug Administ...
Mylan and Pfizer Inc. have announced a definitive agreement to combine Mylan with Upjohn, Pfizer’s off-patent bran...
Sanofi has announced topline results from three Phase 3 trials of ZynquistaTM (sotagliflozin) in adults living with...
Hikma Pharmaceuticals PLC,the multinational generic pharmaceutical company and Civica Rx (Civica, Inc.) have announced a...
A research team led by Tufts University engineers in the US has developed a 3D printed ingestible pill that samples bact...
PerkinElmer, Inc. and EverlyWell, Inc. have announced a new collaboration designed to accelerate innovati...
Cipla USA Inc., a wholly-owned subsidiary of the leading global pharmaceutical company Cipla Limited, announce...
Olon S.p.A., a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization...
Sanofi signed an agreement with Roche for the exclusive over-the-counter (OTC) rights to Tamiflu® for the preve...
Medtronic plc, a global leader in medical technology, and Viz.ai, the emerging leader in applied artificial intelligence...
National Institute of Health researchers have reported the largest genomic study of type 2 diabetes (T2D) in sub-Saharan...
Yellow Wood Partners has entered into a definitive agreement to buy the Dr. Scholl’s™ business from Bayer fo...
Based on new evidence assessing benefits and risks, the WHO recommends the use of the HIV drug dolutegravir (DTG) as the...
Leading European life sciences investment firm Medicxi has announced the closing of Medicxi III, a new €400 million...
